FULC Stock Summary and Trading Ideas (Fulcrum Therapeutics | NASDAQ:FULC)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics trades on the NASDAQ stock market under the symbol FULC.

As of December 13, 2024, FULC stock price declined to $3.96 with 469,955 million shares trading.

FULC has a beta of -1.25, meaning it tends to be less sensitive to market movements. FULC has a correlation of 0.02 to the broad based SPY ETF.

FULC has a market cap of $213.60 million. This is considered a Small Cap stock.

In the last 3 years, FULC traded as high as $24.79 and as low as $2.25.

The top ETF exchange traded funds that FULC belongs to (by Net Assets): IWM, VTI, VXF, XPH, IWN.

FULC has underperformed the market in the last year with a return of -19.8%, while SPY returned +29.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in FULC shares. However, FULC has outperformed the market in the last 3 month and 2 week periods, returning +24.5% and +2.9%, while SPY returned +7.8% and +0.3%, respectively. This indicates FULC has been having a stronger performance recently.

FULC support price is $3.80 and resistance is $4.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FULC shares will trade within this expected range on the day.